Incidence of Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Descriptive Analysis

Basic Details
Date Posted
Monday, November 9, 2020
Status
Complete
Medical Product
apixaban
dabigatran
rivaroxaban
warfarin
Health Outcome(s)
severe uterine bleed
Description

The objective of this analysis was to investigate severe uterine bleeding (SUB) among new users of oral anticoagulants (rivaroxaban, apixaban, dabigatran, and warfarin) in the Sentinel Distributed Database (SDD). This analysis includes two reports:

  • Report 1: We included new users from October 19, 2010 to September 30, 2015. We distributed the request to 17 Data Partners on September 17, 2019.
  • Report 2: We obtained background incidence of SUB outcomes for the previous request (Report 1) from the SDD. The study period included data from October 19, 2010 to September 30, 2015. We distributed the request to 16 Data Partners on March 11, 2020.